Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial

Abstract Background Protection from lethal ventricular arrhythmias leading to sudden cardiac death (SCD) is a crucial challenge after acute myocardial infarction (AMI). Cardiac sympathetic and parasympathetic activity can be noninvasively assessed using heart rate variability (HRV) and heart rate tu...

Full description

Bibliographic Details
Main Authors: Wataru Shimizu, Yoshiaki Kubota, Yu Hoshika, Kosuke Mozawa, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu-ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada, Kuniya Asai, Masaaki Miyamoto, Yasushi Miyauchi, Eitaro Kodani, Masahiro Ishikawa, Mitsunori Maruyama, Michio Ogano, Jun Tanabe, EMBODY trial investigators
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Cardiovascular Diabetology
Subjects:
Acute Myocardial Infarction
Heart rate variability
Heart rate turbulence
Sodium–glucose cotransporter 2 inhibitor
Sudden cardiac death
Randomized Controlled Trial
Online Access:http://link.springer.com/article/10.1186/s12933-020-01127-z

Internet

http://link.springer.com/article/10.1186/s12933-020-01127-z

Similar Items